Grifols to acquire a Novartis diagnostics business unit for USD1.67bn
Grifols is expanding its portfolio by acquiring Novartis' diagnostic products for transfusion medicine and immunology in a deal worth USD1.675bn. The deal, which will be structured through Grifols' diagnostic division and a newly created 100 per cent Grifols-owned subsidiary, includes Novartis’ NAT technology (Nucleic Acid Amplification Techniques), instrumentation and equipment
